Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and ...

On March 24, the Centers for Disease Control and Prevention (CDC) issued a Health Alert Network Health Advisory to clinicians and public health officials regarding the increase in global and U.S.

PD as best response Worse PFS CR/PR as best response Improved PFS ...

Learn more about abstract submission, policies, and guidelines for faculty and presenters.

#ASCO25 will feature nearly 250 oral abstract presentations across Oral Abstract Sessions, Clinical Science Symposia, and the ASCO Plenary Session. Rapid Oral Abstract sessions will also provide over ...

Please review the following abstract policies when preparing your submission. You can also review the Abstract Policy FAQs page for answers to common questions asked by submitters.

Explore resources for getting to Chicago and navigating the ASCO Annual Meeting online and in-person.

Start planning before you arrive at McCormick Place. View the information below so you know where to go for all of your needs while you’re at the Meeting, including onsite childcare and accessibility ...

Formerly the JCO Journals Lounge, JCO Central is a place of community for oncology authors, researchers, or anyone interested in publishing. Meet with JCO Journals editors and discuss manuscript ...

ASCO understands the importance of making connections, sharing ideas, and establishing the foundation for future collaborations, and we're so excited to give you the chance to connect onsite. At ...

View meeting statistics and demographic information for the 2024 Annual Meeting.

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers ...